22 August 2017
Visiongain’s new report The Global Respiratory Inhalers Market, 2017-2027: Revenue prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), By Indication (Asthma and COPD) and Geography 2017-2027 indicates that the Respiratory Inhalers market will see over $33bn in revenue in 2017.
The lead analyst of the report said:
“The advantages of inhalation therapy in the treatment of asthma and COPD have long since been established. In comparison to the oral and parenteral route, the drug dose required in inhalation therapy is lower and rapid onset of action is achieved with minimal unwanted systemic effects. The prevalence of asthma and COPD is growing across the globe and this is further fuelled by the growing ageing population. It is the major factor driving the growth of respiratory inhalers market. Other factors driving the market growth include technological advancements in respiratory inhalation products, growing awareness regarding respiratory diseases, and increasing disposable income in emerging economies.
However, growing pressure to reduce healthcare cost in the developed countries such as the U.S. is impeding the market growth. In addition, high cost of some types of inhalation devices (for instance, dry powder inhalers and nebulizers) is hindering the market growth in the respective product segments; especially in cost-sensitive markets. In addition to this, the market is likely to witness intense competition between generic and branded product manufacturers as some of the current blockbuster products are going off-patent across the forecast period. Thus, though sales will be increasing in terms of volume, the value market is likely to witness sluggish growth.”
The 181-page report contains 118 tables, charts and graphs that add visual analysis in order to explain developing trends within the Respiratory Inhalers. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Respiratory Inhaler submarkets, segmented by product type, with forecasts for Metered Dose Inhalers, Dry Powder Inhalers (including single-dose and multi-dose DPIs) and Nebulizers (Jet, Ultrasonic and Vibrating-Mesh Nebulizers). The respiratory inhalers market is also segmented by Indication with forecasts for Asthma and COPD, as well as other respiratory conditions.
The 181-page report offers market forecasts and analysis for 12 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 7 companies leading the field in respiratory inhaler market in detail.
The Global Respiratory Inhalers Market, 2017-2027: Revenue prospects by Product Type (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizers), By Indication (Asthma and COPD) and Geography 2017-2027 report will be of value to anyone who wants to better understand the respiratory inhalers market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the respiratory inhalers industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.